
Pre-exposure prophylaxis of neutralizing SARS-CoV-2 monoclonal antibodies may be preventative against SARS-CoV-2 transmission, decreasing frequency of new infections and number of hospitalized patients who need antiviral therapies, thus lowering costs.





























